Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06554600 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

StatusRecruiting
PhasePhase 2
Started2024-08-31
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 15, 2024 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.
This is a prospective, multicenter, single-arm, open phase II study to explore the efficacy and safety of Zanubrutinib in combination with Polatuzumab Vedotin, bendamustine, and rituximab (Polo-ZBR) in subjects with relapsed/refractory diffuse large B-cell lymphoma. Subjects with relapsed/refractory DLBCL who met the inclusion/exclusion criteria were screened and treated with 4 courses of Pola-ZBR regimen after signing informed consent. Subjects achieving PR or CR were consolidated with autologous transplantation consolidation or the original regimen for 2 additional courses, and then given Zanubrutinib maintenance therapy for 1 year. The final follow-up was observed until 2 years after enrollment.

Amendment history 1 change detected by DataLookout

2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
Trial Details
NCT Number NCT06554600
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Refractory or Relapsed Diffuse Large B Cell Lymphoma
Enrollment 36 participants
Start Date 2024-08-31
Primary Completion 2026-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-15